Nanopharmaceuticals - Thematic Research
|出版日期||內容資訊||英文 96 Pages
|奈米醫藥品：主題研究 Nanopharmaceuticals - Thematic Research|
|出版日期: 2020年03月01日||內容資訊: 英文 96 Pages||
不久的將來，奈米醫藥品可望在因應由於人口成長導致的慢性病增加中發揮重要作用。其對像不僅只是癌症，也包含糖尿病、關節炎、CV疾病、阿茲海默症、帕金森氏症等。今後將需要一種副作用少的新治療方法，其能改善生活品質 (QoL) 、提升病患治療效果、減輕基礎醫療負擔、降低住院率。此外，透過使用固有抗菌特性、以及作為抗菌劑的有效藥物傳輸系統，奈米藥物亦具有抵抗抗生素抗藥性威脅的潛力。
Nanomedicine is the application of nanotechnology for the diagnosis, prevention, and treatment of disease. This report will focus on the use of nanomedicines for drug delivery and therapeutic purposes, which are often referred to as nanopharmaceuticals, nanodrugs, or nanotherapeutics. Nanopharmaceuticals are defined as drugs or biologics that have been combined with certain synthetic or biological delivery systems, or nanocarriers, in order to impart physical and biological advantages over conventional medicines.
These include enhanced efficacy, reduced toxicity, improved solubility and stability, improved PK/PD, increased circulation time, targeted controlled release and tissue selectivity, and increased intracellular concentration.
The vast majority of marketed and pipeline nanopharmaceuticals are being used to treat a wide range of cancer indications, highlighting the ongoing unmet needs in this area. Other therapy areas include infectious diseases, cardiovascular (CV) and metabolic conditions, ophthalmology, and rare diseases.
A significant proportion of pipeline candidates are in Phase I or Phase II (65%), and almost 70% of the companies are either start-ups or small biopharmaceutical companies. This represents significant opportunities for mergers and acquisitions (M&As) or licensing agreements with larger pharmaceutical companies looking to either invest in innovative nanotechnology or bolster their pipelines with novel therapies.
Novel nanopharmaceuticals allow the implementation of personalized and precision medicine, particularly in cancer. This includes immunoconjugates and the use of nanomaterials as carriers for ribonucleic acid interference (RNAi)-based therapies. Some smart nanocarriers release a drug when triggered by internal or external stimuli, while nano-radioenhancers use the inherent properties of inorganic nanomaterials to treat tumors using local hyperthermia.
In the near future, nanopharmaceuticals will play a key role in the fight against the rise of chronic diseases due to the growing aging population. As well as cancer, this includes diabetes, arthritis, CV disease, Alzheimer's disease, and Parkinson's disease. There is a need for new treatments with reduced side effects that can improve quality of life (QoL), leading to improved patient outcomes, reduced burden on primary care, and reduced hospitalizations.
Nanomedicine also has the potential to combat the threat of antibiotic resistance via the use of nanomaterials with intrinsic antibacterial properties, as well as using nanoparticles as effective drug delivery systems for antibacterial agents.
The Nanopharmaceuticals report provides an assessment of the key industry trends impacting how nanopharmaceuticals are being used in healthcare today, including technological, regulatory, and macroeconomic themes.
Components of the report include -